- EnWave Signs Research Evaluation Agreement With Merck
VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 12, 2011) – EnWave Corporation (TSX-V:ENW)(FRANKFURT:E4U) (“EnWave”, or the “Company”) today announced that it has signed a Research Evaluation Agreement with Merck, through a subsidiary. Under the terms of the agreement Merck will conduct a field test to determine the feasibility of the Radiant Energy Vacuum (“REV”) Technology using EnWave’s [...]
- IntelGenx Announces FDA Approval Of Its High Dose Anti-Depressant CPI-300
SAINT LAURENT, Quebec, Nov. 11, 2011 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) (“IntelGenx”) today announced that the U.S. Food and Drug Administration (FDA) has approved IntelGenx’ lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the [...]
Bridge Relations is a proactive investor relations firm capable of effectively marketing its clients in Europe and North America. The firm is the meshing of two successful investor relations professionals – one from North America the other from Europe – who have combined their investor networks, skills, and passion for investor relations into one cohesive cross-Atlantic firm.
